论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
糖皮质激素在 COVID-19 肺炎恶化早期的临床疗效
Authors Liu Z, Shi F, Liu JX, Liu JQ, Li J, Wang Q, Wang H, Gao CL, Li JM, Zhao DF
Received 12 April 2021
Accepted for publication 24 June 2021
Published 12 July 2021 Volume 2021:14 Pages 2667—2674
DOI https://doi.org/10.2147/IDR.S314938
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Héctor M. Mora-Montes
Background: The World Health Organization (WHO) strongly suggests using corticosteroids in patients with severe coronavirus disease 2019 (COVID-19). Similarly, a large randomized controlled clinical trial (RCT) in the UK found that dexamethasone effectively reduced the mortality rate in severe COVID-19 patients. However, the safety profile of corticosteroids has been a controversial area of study.
Case Description: A case of a COVID-19 patient is described and the clinical characteristics are observed as the mildly symptomatic patient progresses into a critically ill patient and during their dramatic improvement with corticosteroid therapy in the early stage of the deterioration process with COVID-19 pneumonia.
Conclusion: The most suitable timing and dosage for the use of corticosteroids to maximize its effect during the worsening of COVID-19 pneumonia are discussed. One of the main pathophysiological hypotheses for severe COVID-19 patients is related to cytokine storm and virus load, which can be effectively treated with corticosteroid therapy.
Keywords: COVID-19 pneumonia, cytokine storm, corticosteroids, clinical characteristics